Alembic Pharmaceuticals Limited (APLLTD) — Announcement

· NSE 🔴 High Importance Neutral
📢 Key Event
CRISIL reaffirmed AA+/Stable rating on enhanced Rs. 1,100 crore bank loan and A1+ rating on commercial paper
🔄 What Changed
Enhanced bank loan limit from Rs. 800 crores to Rs. 1,100 crores
🔮 What's Next
Rating remains valid for 60 calendar days for CP issuance; revalidation required if not placed within 180 days
💡 Investor Takeaway
The reaffirmation confirms strong creditworthiness and expanded borrowing capacity, supporting financial stability for investors.

Alembic Pharmaceuticals reaffirmed its CRISIL AA+/Stable rating on a revalued Rs. 1,100 crore bank loan facility and CRISIL A1+ rating on Rs. 1,100 crore commercial paper, reflecting enhanced credit capacity and no change in outlook. The reaffirmation underscores stable financing conditions for shareholders.

📄 View Original Announcement (PDF)

About Alembic Pharmaceuticals Limited (APLLTD)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹15,412.51 Cr P/E: 22.9 ROE: 11.8% ROCE: 11.2%

View full APLLTD stock details →

📡 Get AI alerts when APLLTD files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track APLLTD — Free

📊 More APLLTD filings

See all APLLTD filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when APLLTD files new disclosures

Track APLLTD filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track APLLTD — Free

Free account · 2 AI queries/day